Vaccine Info


PAMVAC is a vaccine candidate based on a recombinant fragment of VAR2CSA, the Plasmodium falciparum protein responsible for binding to the placenta via chondroitin sulfate A (CSA).

PAMVAC was found safe during a phase 1 Clinical Trial.

PAMVAC formulated with Alhydrogel or GLA-based adjuvants was safe, well-tolerated and induced functionally active antibodies. PAMVAC will next be assessed in women before first pregnancies in an endemic area.

April 8th, 2019